Good Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Good Therapeutics was a Seattle-based biopharmaceutical company developing a new class of conditionally active therapeutics. Its regulated, context-dependent molecules combined an antibody sensor directed against a specific marker with a therapeutic component that became active only when the sensor bound its target. The lead program was a PD-1-regulated IL-2 therapeutic for immuno-oncology. The company was founded by John Mulligan and raised about $30.2 million in venture funding.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Acquired by Roche
On September 7, 2022 Good Therapeutics announced a definitive merger agreement to be acquired by Roche: a $250 million upfront cash payment for the shares plus milestone payments, giving Roche rights to the PD-1-regulated IL-2 program and exclusive platform rights; the deal was expected to close in Q3 2022.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.